Teva’s severe eosinophilic asthma drug Cinqaero wins EU approval
Teva Pharmaceutical Industries has announced that the European Commission has granted marketing authorisation for their asthma drug, Cinqaero (reslizumab) in the 28 countries of the European Union (EU) in addition to Norway, Liechtenstein and Iceland.
Click on this link for more information.
